Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as wel… Read more
Allergy Therapeutics plc - Asset Resilience Ratio
Allergy Therapeutics plc (AGYTF) has an Asset Resilience Ratio of 0.00% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2023)
This chart shows how Allergy Therapeutics plc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Allergy Therapeutics plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Allergy Therapeutics plc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Allergy Therapeutics plc Industry Peers by Asset Resilience Ratio
Compare Allergy Therapeutics plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Allergy Therapeutics plc (2007–2023)
The table below shows the annual Asset Resilience Ratio data for Allergy Therapeutics plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 0.30% | $200.00K | $66.77 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $68.50 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $51.02 Million | -- |
| 2017-06-30 | 0.71% | $404.00K | $57.18 Million | -7.57pp |
| 2016-06-30 | 8.28% | $4.69 Million | $56.68 Million | +6.73pp |
| 2015-06-30 | 1.54% | $783.00K | $50.70 Million | +0.33pp |
| 2014-06-30 | 1.21% | $345.00K | $28.40 Million | +1.21pp |
| 2013-06-30 | 0.01% | $2.00K | $28.96 Million | -1.73pp |
| 2012-06-30 | 1.74% | $483.00K | $27.75 Million | +1.73pp |
| 2008-06-30 | 0.01% | $3.00K | $23.18 Million | -0.25pp |
| 2007-06-30 | 0.26% | $63.00K | $23.99 Million | -- |